This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.
A Phase I/II Study of Hyperpolarized 13C MRI As a Biomarker of Aggressiveness & Response to Therapy in Patients with Advanced Solid Tumors
PRIMARY OBJECTIVES:
Phase I/Part A
- To optimize the signal-to-noise ratio in detecting intra-tumoral hyperpolarized 13C pyruvate/lactate signal and hyperpolarized urea area under the curve (AUC) using metabolic magnetic resonance (MR) imaging in patients with advanced solid tumors.
Phase II/Part B
- To determine the mean percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio,pyruvate-to-lactate kinetic constant (kPL) and urea AUC after initiation of usual care/standard of care (SOC) treatment
SECONDARY OBJECTIVES:
Phase I/Part A
- To further characterize the safety profile of hyperpolarized 13C-pyruvate +/- 13C,15N-urea.
- To determine the reproducibility of intra-tumoral HP lac/pyr ratio with same-day repeated dose studies.
Phase II/Part B
- To study the association between clinical outcomes and the percent change from baseline in peak intra-tumoral hyperpolarized lactate-to pyruvate ratio and kPL (+/-correction for HP urea AUC) after initiation of SOC treatment.
- To further characterize the safety profile of hyperpolarized 13C pyruvate +/- 13C,15N-urea.
- To determine the reproducibility of intra-tumoral HP lac/pyr ratio and/or HP urea AUC with same-day repeated dose studies.
OUTLINE:
Participants will be enrolled in Part A which is the feasibility, run-in study which includes the iterative adjustment of coil design to optimize imaging parameters within the target tumor lesion(s). If the data from Part A supports further investigation, additional participants will be enrolled in Part B which is a biomarker cohort which includes participants who are planning on being treated with either standard-of-care (SOC) or investigational therapies and will be followed until discontinuation of the treatment regimen outside of this protocol.